Journal of Clinical Oncology
Articles in this Issue
Ultra-hypofractionated versus hypofractionated radiotherapy in breast cancer: Real-world toxicity, efficiency, and implementation patterns.
e12722 Background: Hypofractionated regimens are standard for breast-conserving therapy due to equivalent efficacy and red...
A prospective, multi-center, phase Ib/II trial of first-line cadonilimab plus axitinib in advanced non–clear cell renal cell carcinoma.
4501 Background: Non-clear cell renal cell carcinoma (nccRCC) is a rare and heterogeneous disease with limited treatment e...
Time toxicity in patients with advanced pancreatic cancer in Mexico.
4214 Background: Advanced pancreatic ductal adenocarcinoma (PDAC) remains one of the most lethal malignancies despite adva...
Carcinoma with osteoclast-like giant cells.
e16392 Background: Carcinoma with osteoclast-like giant cells (COGC) is a rare, undifferentiated malignancy composed of at...
INTerpath-013: A phase 2, randomized, double-blind study of intismeran autogene plus pembrolizumab and chemotherapy as first-line treatment for metastatic squamous non–small cell lung cancer.
TPS8670 Background: Non–small-cell lung cancer (NSCLC) is the leading cause of cancer mortality worldwide. The anti-PD-1 p...
The DUET-1 trial: Feasibility and toxicity outcomes and early oncological outcomes of <sup>177</sup> lutetium-PSMA radioligand therapy (RLT) alternated with <sup>233</sup> radium-dichloride in patients with metachronous oligorecurrent osseus hormone sensitive prostate cancer (mHSPC).
e17083 Background: Currently, no available therapy has been shown to significantly improve long-term oncological outcomes...
A head-to-head comparison of sextant-systematic biopsy versus extended-systematic biopsy for prostate cancer diagnosis in the era of MRI-targeted biopsy: Non-inferiority randomized clinical trial.
5120 Background: In recent years, combined targeted biopsy (TB) and 12-core extended systematic biopsy (SB) (TB+12SB) has...
Health system inequities as a mediator of age-related survival differences in high-grade serous ovarian cancer: Chile as a case study for Latin America.
e17597 Background: Health system inequities are major drivers of cancer outcomes in Latin America, where rapidly ageing po...
Hospital-acquired sepsis as a driver of failure-to-rescue in AML and MDS: A national inpatient sample analysis, 2016–2023.
e23219 Background: Sepsis is a frequent proximate cause of inpatient death in acute myeloid leukemia (AML) and myelodyspla...
Impact of corticosteroid and tocilizumab use on infection incidence and outcomes following CAR T-cell therapy with axicabtagene ciloleucel.
e19007 Background: Corticosteroids and tocilizumab are frequently used to manage cytokine release syndrome (CRS) and immun...
ERBIOTAX (TTCC-2022-02): A phase II, multicenter, randomized study of cetuximab with or without weekly paclitaxel after progression on first-line pembrolizumab plus platinum/5-FU in recurrent or metastatic head and neck squamous cell carcinoma.
TPS6131 Background: Pembrolizumab, with or without platinum–5FU (PF), is the current first-line (1L) standard of care for...
Impact of central review process on response rates in neuroblastoma clinical trials: A report from NANT Consortium.
10044 Background: Accurate and reproducible response assessment is critical for evaluating efficacy in clinical trials. Ce...
Dose-response relationship of serum iron, ferritin, and transferrin saturation with cancer-related mortality: An analysis of population-based data.
11043 Background: Altered iron homeostasis has been linked to cancer outcomes, with epidemiologic evidence suggesting that...
Preliminary results of an open-label, single-arm phase 2/3 trial (SPARK-ALL) of calaspargase pegol in adults with newly diagnosed Philadelphia chromosome–negative acute lymphoblastic leukemia.
6529 Background: Asparaginase is an important component of many regimens for acute lymphoblastic leukemia (ALL). In patien...
Sex differences in immune-related adverse events requiring hospitalization among patients with checkpoint inhibitor-sensitive malignancies: A national analysis.
11169 Background: Immune checkpoint inhibitors (ICIs) can cause immune-related adverse events (irAEs) with significant mor...
Final results from ZZFIRST: A randomized phase 2 trial of enzalutamide (EZ) and talazoparib (TALA) in metastatic hormone-naïve prostate cancer (mHNPC).
5006 Background: ADT plus AR pathway inhibition (ARPI) improves outcomes in mHNPC, yet responses remain heterogeneous. AR–...
A machine learning–enhanced analysis of temporal trends in biomarker-based eligibility restrictions in oncology clinical trials.
11019 Background: The adoption of biomarker-based eligibility criteria reflects the evolution of precision oncology, but t...
Racial, socioeconomic, and geographic disparities in survival among patients with ampullary carcinoma: A population-based SEER analysis (2000–2022).
e16483 Background: Ampullary carcinomas (AC) are rare malignancies comprising ~0.2% of GI cancers with limited population-...
Digital delivery of personalized cancer risk reduction: Real-world engagement with ACS CancerRisk360.
e22515 Background: Access to personalized, disease site agnostic guidance to lower cancer risk remains an unmet public hea...
A phase 1b, two-arm study of tolododekin alfa (ANK-101) in combination with an anti–PD-1/PD-L1 antibody in participants with advanced non–small cell lung cancer (NSCLC).
TPS2678 Background: Tolododekin alfa (ANK-101) is an anchored immunotherapy linking IL-12 to aluminum hydroxide through an...
Patterns of failure and outcomes in triple-negative compared to estrogen receptor–positive breast cancer.
e12760 Background: Advances in molecular classification have led to subtype-specific treatments for breast cancer, improvi...
Breaking the stromal barrier in bladder tumor with a urea-powered platelet nanomotor for potentiated BCG immunotherapy.
e16604 Background: Intravesical Bacillus Calmette-Guérin (BCG) therapy for bladder cancer is severely limited by poor tumo...
Targeting cellular senescence to enhance skeletal muscle recovery in survivors of breast cancer: An ancillary study of the phase II randomized PROFFi clinical trial.
TPS12168 Background: Postmenopausal survivors of breast cancer frequently experience persistent physical function decline...
Arrhythmia phenotype and 30-day readmission in selected cancers: Propensity-matched NRD study.
11180 Background: Cardiac arrhythmias are common in oncology and may increase rehospitalization and resource use, but arrh...
Time to treatment for primary melanoma in an integrated healthcare system.
e21577 Background: Delayed treatment intervention for primary melanoma may negatively impact prognosis. This study investi...